Methicillin-Resistant Staphylococcus Aureus (MRSA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

ReportLinker
Updated 2 min read
0
ReportLinkerReportLinker
ReportLinker

Summary This reports provides a data-driven overview of the current and future competitive landscape in MRSA therapeutics. Synopsis - In 2022, there will be more than 859,000 incident cases of MRSA across seven major pharmaceutical markets.

New York, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Methicillin-Resistant Staphylococcus Aureus (MRSA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape" - https://www.reportlinker.com/p06325933/?utm_source=GNW

- There are eight leading marketed drugs for the treatment of MRSA; Pfizer is a key player in the disease space.
- R&D activity in MRSA is steady, with six products in late-stage (Phase III and pre-registration) development.
- Commercial sponsor dominate clinical trial development in MRSA, with the US emerging as the key countries for conducting trials in MRSA.
- In deals involving MRSA assets, partnerships were the most common type of deal in Asia-Pacific and Europe, while licensing agreements were predominant in North America.
- Therapeutic options for MRSA patients continue to be limited, with no new therapies reaching the market.

Scope
Methicillin-Resistant Staphylococcus Aureus (MRSA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Pricing and Reimbursement Assessment
- Retail or Manufacturer Price of Products
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts

Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the MRSA market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MRSA market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Read the full report: https://www.reportlinker.com/p06325933/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Advertisement

Recommended Stories

  • Jeff Bezos' Most Prized Possession Breaks Historical Auction Records At Almost $53 Million

    Jeff Bezos amassed his wealth through Amazon stocks and owns hundreds of millions of dollars worth of real estate, but one of his most valuable possessions may surprise you: art. Among his collection is the renowned piece "Hurting the Word Radio #2 (1964)" by Ed Ruscha, purchased by Bezos for almost $53 million. This artwork, a prime example of Ruscha’s text-based paintings, stands as a signature piece in Bezos’ collection. As concerns over stock market volatility persist, the world’s wealthiest

  • Warren Buffett's Latest $2.6 Billion Buy Brings His Total Investment in This Stock to More Than $77 Billion in Under 6 Years

    The Oracle of Omaha has purchased shares of his favorite stock for 23 consecutive quarters.

  • Massive News for Intel Stock Investors

    Intel was hit with more bad news that has enormous implications for investors.

  • Anthropic now lets kids use its AI tech -- within limits

    AI startup Anthropic is changing its policies to allow minors to use its generative AI systems -- in certain circumstances, at least. Announced in a post on the company's official blog Friday, Anthropic will begin letting teens and preteens use third-party apps (but not its own apps, necessarily) powered by its AI models so long as the developers of those apps implement specific safety features and disclose to users which Anthropic technologies they're leveraging. In a support article, Anthropic lists several safety measures devs creating AI-powered apps for minors should include, like age verification systems, content moderation and filtering and educational resources on "safe and responsible" AI use for minors.

  • QuantumScape Making Big Moves: Time to Buy Before It Skyrockets?

    The battery start-up might reach its ambitions sooner than expected.

  • 3 Artificial Intelligence (AI) Stocks That Could Make You a Millionaire

    Many different types of stocks can mint millionaires -- from big to small.

  • Bluesky now lets you personalize main Discover feed using new controls

    Bluesky is now allowing users to personalize their main Discover feeds. The social network is rolling out an updated version of its app that lets users offer feedback about its algorithmic feed so they can better customize it using "Show more like this" and "Show less like this" buttons in a post's menu to choose which content the algorithm surfaces. The change will help Bluesky users create a timeline that takes into consideration their own preferences, not what the company thinks they should see.

  • I Finally Decided to Cut My Losses and Sell This Stock -- Here's Why

    This real estate technology company could be hit hard by a changing real estate market.

  • Stock Market News for May 10, 2024

    Wall Street closed sharply higher on Thursday, with interest rates still dominating the proceedings.

  • Apple Says No Major App Developers Accept New Outside Payments

    (Bloomberg) -- No major app developers have signed up to use outside payment options that Apple Inc. introduced earlier this year for its App Store because the fees they pay would be at least as high as they were before, according to testimony presented to a federal judge.Most Read from BloombergElon Musk Pledges to Grow Supercharger Business He Just DecimatedApple Nears Deal With OpenAI to Put ChatGPT on iPhoneIce Cube’s Big3 Basketball League Sells Its First Team in $10 Million DealBiden Set t